Clinical trials: Transmission, Other/Miscellaneous
HIV Infections
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
The purpose of this study is to provide early access to TMC114 (a protease inhibitor) for HIV-1 infected patients with limited or no treatment options, who have failed multiple antiretroviral (ARV) regimens, and to evaluate the…
- Trial name
- NCT00245739
- Testing
- TMC-114
- Where
- 394 sites in United States, Belgium and 20 more
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations
The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get…
- Trial name
- NCT00011089
- Testing
- Tenofovir disoproxil fumarate
- Where
- United States
- Sponsor
- Gilead Sciences
HIV Infections, AIDS-Associated Nephropathy
A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease
The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney…
- Trial name
- NCT00002397
- Testing
- Nelfinavir mesylate, Saquinavir, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
HIV, AIDS
Kaiser Permanente HIV Cohort Study
Human Immunodeficiency Virus (HIV) infected patients in the Kaiser Permanente HIV registry wil be followed in the usual clinical care to estimate the rates of specified clinical events.
- Trial name
- NCT01339403
- Testing
- non-interventional trial
- Volunteers
- 282,368 people
- Sponsor
- ViiV Healthcare
HIV Infections
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients.
- Trial name
- NCT01524900
- Where
- 53 sites in Austria, Poland and 1 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of…
- Trial name
- NCT00002364
- Testing
- Abacavir sulfate
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both.
- Trial name
- NCT00002334
- Testing
- Saquinavir, Zidovudine, Zalcitabine
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 3,000 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
- Trial name
- NCT00004852
- Testing
- Efavirenz, Lamivudine, Zidovudine
- Where
- 66 sites in United States, Argentina and 3 more
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.
- Trial name
- NCT00004998
- Testing
- Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
- Where
- 10 sites in United States, Dominican Republic
- Volunteers
- 30 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1 Infection
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks.
- Trial name
- WIP (NCT01213316)
- Testing
- Raltegravir
- Volunteers
- 451 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved…
- Trial name
- NCT00062660
- Testing
- Tipranavir
- Where
- 146 sites in United States, Australia and 10 more
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants
This is a 3 part study of an investigational capsid inhibitor, VH4004280, in healthy adult participants. The purpose is to evaluate the effect of tablet formulation as well as food on bioavailability.
- Trial name
- NCT06168318
- Testing
- VH4004280 Formulation A, VH4004280 Formulation B, VH4004280 Formulation C
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
To offer an investigational agent (saquinavir) to people with HIV/AIDS who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials.
- Trial name
- NCT00002382
- Testing
- Saquinavir
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Hoffmann-La Roche
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
HIV Infections
A Study of 141W94 in Combination With Other Anti-HIV Drugs
To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing.
- Trial name
- NCT00002372
- Testing
- Indinavir sulfate, Amprenavir, Nelfinavir mesylate
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Glaxo Wellcome
HIV Infection
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
- Trial name
- NCT00100984
- Testing
- FUZEON [enfuvirtide]
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
- Trial name
- NCT00002412
- Testing
- Emivirine, Hydroxyurea, Stavudine
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
Mycoses, HIV Infections
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts < 250 cells/mm3 who are…
- Conditions
- Mycoses, HIV Infections, Coccidioidomycosis
- Trial name
- NCT00002325
- Testing
- Fluconazole
- Where
- 3 sites in United States
- Sponsor
- Pfizer
HIV Infections
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
- Trial name
- NCT00002453
- Testing
- Tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus, HIV Infections
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
This study is a Phase IIb, randomized, multicentre, parallel group, open-label, study having an overall objective to evaluate the antiviral activity, tolerability, and safety of two intramuscular (IM) dosing regimens of GSK744 LA…
- Trial name
- NCT02120352
- Testing
- CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 309 people
- Sponsor
- ViiV Healthcare